2017, Number 2
<< Back Next >>
Rev Cuba Endoc 2017; 28 (2)
Nutritional state and vascular risk factors of patients admitted to the Center of Diabetic Care in Havana
Conesa GAI, Yanes QM, Zayas TGM, González PK, Domínguez AE
Language: Spanish
References: 47
Page: 1-13
PDF size: 221.76 Kb.
ABSTRACT
Introduction: obesity and diabetes is a frequent and lethal association that, in
turn, is related to other factors increasing the cardiovascular risks.
Objective: to characterize the nutritional state and to identify vascular risk factors
in diabetic persons who were admitted to the Center of Diabetic Care in Havana.
Methods: cross-sectional and descriptive study that reviewed 1 916 medical
histories and the studied variables were type of diabetes, body mass index, waist
circumference, blood hypertension, smoking, hypercholesterolemia, glycemic
control and urinary excretion of albumin.
Results: in the study group, 88.2 % of patients suffered type 2 diabetes, 74.5 %
of them was overweighed or obese; 62.5 % had increased waist circumference;
67.2 % were hypertensive; 55.2 % had no glycemic control; 50.6 % had
hypercholesterolemia; 44.4 % were smokers and 27.6 % had urinary excretion of
albumin. Type 1 diabetes was present in 11.8 %; 66.4 % of the latter were
normoweighed; 57.5 % had no glycemic; 33.7 % were overweighed or obese;
31.4 % showed urinary excretion of albumin; 29.9 % hypercholesterolemia;
28.7 % were smokers and 23.9 % hypertensive whereas 21.2 % had increased
waist circumference.
Conclusions: most of patients had type 2 diabetes and overweight, with abdominal
obesity. The association of several risk factors was very common, regardless of the
type of diabetes. Effective strategies must be designed to treat diabetes and the
associated risk factors in a comprehensive way.
REFERENCES
Akter S, Rahman M, Krull S, Sultana P. Nationwide Survey of Prevalence and Risk Factors for Diabetes and Prediabetes in Bangladeshi Adults. Diabetes Care. 2014;37(1):9-10.
Asociación Latinoamericana de Diabetes. Guías ALAD de diagnóstico, control y tratamiento de la diabetes mellitus tipo 2. Organización Panamericana de la Salud [homepage en Internet]; ALAD, 2008 [citado 15 de abril de 2014]. Disponible en: http://www.paho.org/spanish/ad/dpc/nc/dia-guia-alad.pdf
Boyle J, Thompson T, Gregg E, Barker L, Williamson D. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Population Health Metrics. 2010;8:29-41.
Colectivo de autores. The global burden. Diabetes Atlas. 2ª edición. Bruselas: International Diabetes Federation; 2013. p. 24-31.
Orlandi N, Álvarez E, González TM, González K. Guías de práctica clínica. Diabetes Mellitus tipo 2. La Habana: Editorial Ciencias Médicas; 2012.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;(5):1047-53.
Colectivo de autores. International Diabetes Federation. IDF Diabetes Atlas update poster. 6th ed [homepage en Internet]; Brussels, International Diabetes Federation, 2014 [citado 15 de abril de 2014]. Disponible en: http://www.idf.org/diabetesatlas/
Organización Panamericana de la Salud. Estrategia regional y plan de acción para un enfoque integrado. Sobre la prevención y el control de las enfermedades crónicas. Washington, DC: OPS; 2007.
Perdigón G, Fernández S. Recent evolution of the behavior of diabetes mellitus in Mexico during childhood and adolescence (1990-2007). Bol Med Hosp Infant Mex. 2009;66:293-6.
Cuba (Minsap). Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud de Cuba; 2014.
Gil LE, Sil MJ, Domínguez ER, Torres LP, Medina JH. Guía de práctica Clínica. Diagnóstico y tratamiento de la diabetes mellitus tipo 2. Rev Med Inst Mex Seguro Soc. 2013;51(1):104-19.
Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25(12):2165-71.
American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2012;35(sup 1):S64-S71.
Alegría E, Castellano JM, Alegría A. Obesidad, síndrome metabólico y diabetes: implicaciones cardiovasculares y actuación terapéutica. Revista Española de Cardiología. 2008;61(7):752-64.
Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, et al. American Association of Clinical Endocrinologists. Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract. 2011;17:287-302.
McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study. N Engl J Med. 1971;285:1441-6.
De Fronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetol. 2010;53:1270-87.
Calderín O, Monteagudo G, Yanes M, García J, Marichal S, Cabrera E, et al. Síndrome metabólico y prediabetes. Rev Cubana Endocrinol. 2011;22(1):52-7.
Grundy S. Pre-Diabetes, Metabolic Syndrome and Cardiovascular Risk. J Am Coll Cardiol. 2012;59(7):635-43
The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J. 2007;28:88-136.
David McCarthy H, Ellis SM, Cole TJ. Central overweight and obesity in British youth aged 11-16 years: cross sectional surveys of waist circumference. BMJ. Mar 2003;326:624.
Centrers for Disease Control and Prevention (CDC). About BMI for Adults [homepage en Internet]; CDC September 13, 2011 [citado 20 de septiembre de 2013]. Disponible en: https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html
Fasce E, Fasce F, Zarate H, Campos I, Flores M, Ibañez P. Relación entre perímetro abdominal y nivel socioeconómico y presión arterial. Rev Chil Cardiol. 2010;29:11-8.
Faget O. El Centro de Atención al Diabético de la Habana y el Programa Nacional de Diabetes. Rev Cubana Endocrinol. 1998;9(2):101-2.
American Diabetes Association. Standards of Medical Care in Diabetes 2013. Diabetes Care. 2013;36(sup 1):S11-S14.
Pérez B. Epidemiology and physiopathology of diabetes mellitus type 2. Rev Med Clin Condes. 2009;20(5):565-71.
Campbell R. Type 2 diabetes: Where we are today: An overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc. 2009;49(supp 1):S3-S9.
Barrio R, Ros P. Diabetes tipo 2 en población pediátrica española: cifras, pronóstico y posibilidades terapéuticas. Av Diabetol [serie en Internet]. 2013 [citado 22 de septiembre de 2015];29(2). Disponible en: http://www.sciencedirect.com/science/article/pii/S1134323013000045
Aschner P. Epidemiología de la diabetes en Colombia. Av Diabetol. 2010;26(2):95-100.
Farmer A, Fox R. Diagnóstico, clasificación y tratamiento de la diabetes. BMJ. 2011;342:d3319.
Pérez A, Alonso L, García AJ, Garrote I, González S, Morales JM. Intervención educativa en diabéticos tipo 2. Rev Cub Med Gen Integr. 2009;25(4):17-29.
Justo I, Orlandi N. Diabetes y obesidad. Estudio en un área de salud. Rev Cubana Med Gen Integr. 2005;21(5-6):13-6.
Socarrás SM, Blanco AJ, Vázquez VA. Factores de riesgo de enfermedad aterosclerótica en la diabetes mellitus tipo 2. Rev Cubana Med. 2003:42(2):108-12.
Moreno MI. Circunferencia de cintura: una medición importante y útil de riesgo cardiometabólico. Rev Chil Cardiol. 2010;29(1):85-7.
Hermans MP, Ahn SA, Rousseau MF. The atherogenic dyslipidemia ratio [lo(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids in Health and Disease. 2012;11:132.
Quinto Grupo de Trabajo de la Sociedad Europea de Cardiología y Otras Sociedades sobre la Prevención de la Enfermedad Cardiovascular en la Práctica Clínica. Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica (versión 2012). Rev Esp Cardiol. 2012;65(10):937.e1-e66.
Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, et al. American Association of Clinical Endocrinologists. Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract. 2011;17:287-302.
Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Syst Rev. 2013;(37):1-126.
Crespo N, Rosales E, Fernández R, Crespo N, Hernández JD. Caracterización de la Diabetes Mellitus. Rev Cubana Med Gen Integr [serie en Internet]. 2003 [citado 20 de julio de 2005];19(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 21252003000400004&lng=es&nrm=iso&tlng=es
Crespo N, Martínez A, Rosales E, Crespo N, García J. Diabetes mellitus e hipertensión arterial. Estudio en el nivel primario de salud. Rev Cubana Med Gen Integr [serie en Internet]. 2002 [citado 20 de julio de 2005];18(5). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 21252002000500007&lng=es&nrm=iso&tlng=es
Licea ME, Singh O, Smith A, Martínez R. Frecuencia y características clínicas y resultados terapéuticos de la hipertensión arterial en diabéticos tipo2. Rev Cubana Endocrinol. 2002;13:144-68.
Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, De Boer MJ, et al. Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares. Rev Esp Cardiol. 2007;60:525-64.
Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo J, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761-88.
Millán J, Alegría E, Guijarro C, Lozano JV, Vitale GC, González-Timón B, et al. Dyslipidemia in diabetics treated with statins. Results of the Dyslipidemia International Study in Spain. Med Clin (Barc). 2012;12:S0025-7753.
III Consenso Nacional para el Manejo del Paciente con Dislipidemia. Dislipidemia aterogénica: diabetes tipo 2 y prediabetes. Avances Cardiol. 2014;34(2):S91-S100.
González A, Simental LE, Elizondo S. Relación triglicéridos/colesterol-HDL elevada y resistencia a la insulina. Cir Cir. 2011;79(2):126-31.
Arnaiz P, Acevedo M, Barja S, Aglony M, Guzmán B, Cassis B, et al. Adiponectin levels, cardiometabolic risk factors and markers of subclinical atherosclerosis in children. I Int J Cardiol. 2010;138:138-44.